Organigram Global Inc. OGI PHARMA
Company Overview
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
Why Investors Should Care
Generates a return on equity of 17.6%, reflecting efficient use of shareholder capital.
Revenue has grown at a 48.5% CAGR over the past five years.
Trades at a P/E of 2.6, below the sector median of 24.8.
Maintains a net profit margin of 28.0%.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Sep 2025 Revenue of $259.18M (+62.2% YoY); net profit $-24.76M.
- Trailing 12 Months Year-on-year growth — revenue +49.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 48.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 48.49% |
| 1 Year: | 49.40% |
Stock Price Performance
| 1 Year: | -30.00% |
| 6 Months: | -22.22% |
| 3 Months: | +4.67% |
| 1 Month: | +13.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)44.81 · Neutral
P/E of 2.60 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 28.0%.
- Compounding revenue at 48.5% over 5 years.
CONS
- Trading 46.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OGI Organigram Global Inc. PHARMA | 1.12 | 2.60 | $157.93M | 0.00% | -3.51% | 17.56% | 48.49% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 65.60M | 70.79M | 80.06M | 63.54M | 59.79M |
| Cost of Revenue | - | 47.18M | 44.65M | 48.22M | 40.22M | 43.39M |
| Gross Profit | - | 18.42M | 26.15M | 31.84M | 23.32M | 16.41M |
| Operating Expenses | - | 26.00M | 28.25M | 30.65M | 26.73M | 26.20M |
| Operating Income | - | -7.58M | -2.10M | 1.19M | -3.42M | -9.79M |
| EBITDA | - | -2.74M | 2.68M | 6.15M | 1.56M | -4.76M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | 42.35M | -16.20M | -41.73M | 19.97M | -921.00K |
| Tax Provision | 0 | -106.00K | -9.90M | -3.76M | - | 0 |
| Net Income | - | 42.46M | -6.29M | -37.96M | 19.97M | -921.00K |
| Diluted EPS | -0.20 | 0.32 | -0.05 | - | 0.15 | -0.01 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Aug 2021 | Aug 2022 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 79.16M | 145.81M | 159.84M | 259.18M |
| Cost of Revenue | 107.56M | 114.24M | 112.32M | 168.97M |
| Gross Profit | -28.40M | 31.57M | 47.52M | 90.22M |
| Operating Expenses | 44.44M | 70.32M | 82.28M | 105.52M |
| Operating Income | -72.84M | -38.75M | -34.76M | -15.30M |
| EBITDA | -96.71M | 10.96M | -22.68M | 2.67M |
| Interest Expense | 2.96M | 429.00K | - | - |
| Pretax Income | -130.70M | -14.37M | -45.44M | -38.53M |
| Tax Provision | 0 | -88.00K | 0 | -13.77M |
| Net Income | -130.70M | -14.28M | -45.44M | -24.76M |
| Diluted EPS | -2.04 | -0.18 | -0.48 | -0.19 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2021 | Aug 2022 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Total Assets | 554.02M | 577.11M | 407.86M | 562.21M |
| Current Assets | 260.62M | 221.62M | 262.22M | 284.90M |
| Cash & Equivalents | 55.37M | 68.52M | 106.75M | 28.20M |
| Inventory | 48.82M | 68.28M | 82.52M | 123.95M |
| Receivables | 20.20M | 43.86M | 32.66M | 63.59M |
| Total Liabilities | 74.21M | 69.05M | 101.87M | 213.08M |
| Current Liabilities | 26.27M | 55.28M | 53.32M | 126.16M |
| Long Term Debt | 230.00K | 155.00K | 25.00K | - |
| Total Debt | 5.95M | 3.36M | 4.46M | 8.75M |
| Total Equity | 479.81M | 508.06M | 305.99M | 349.13M |
| Shares Outstanding | 74.70M | 78.45M | 108.59M | 134.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Aug 2021 | Aug 2022 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -28.59M | -36.21M | 3.87M | -7.59M |
| Investing Cash Flow | -115.11M | 44.03M | -30.80M | -81.07M |
| Financing Cash Flow | 174.46M | 5.33M | 107.78M | 39.33M |
| Capital Expenditure | -12.29M | -48.78M | -5.34M | -17.05M |
| Free Cash Flow | -40.88M | -84.99M | -1.47M | -24.64M |
| Net Change in Cash | 30.77M | 13.15M | 80.85M | -49.32M |
Ratios (Annual)
Figures in %.
| Metric | Aug 2021 | Aug 2022 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Gross Margin % | -35.9% | 21.7% | 29.7% | 34.8% |
| Operating Margin % | -92.0% | -26.6% | -21.7% | -5.9% |
| Net Margin % | -165.1% | -9.8% | -28.4% | -9.6% |
| ROE % | -27.2% | -2.8% | -14.9% | -7.1% |
| ROCE % | -13.8% | -7.4% | -9.8% | -3.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tidal Investments LLC | 1.53% | 2.16M | $2.27M |
| 2 | Renaissance Technologies, LLC | 1.02% | 1.44M | $1.52M |
| 3 | AdvisorShares Investments, LLC | 0.63% | 888.06K | $932.46K |
| 4 | Goldman Sachs Group Inc | 0.43% | 611.48K | $642.05K |
| 5 | Morgan Stanley | 0.22% | 308.11K | $323.51K |
| 6 | Baader Bank Aktiengesellschaft | 0.18% | 250.00K | $262.50K |
| 7 | Bank of Montreal /CAN/ | 0.17% | 238.43K | $250.35K |
| 8 | UBS Group AG | 0.15% | 208.77K | $219.21K |
| 9 | Dimensional Fund Advisors LP | 0.12% | 164.14K | $172.34K |
| 10 | Formidable Asset Management, Llc | 0.11% | 160.31K | $168.33K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OGI
A cannabis company will stream its global strategy Sept. 30, with leaders expected to answer questions. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPU3k0aWxHaThvcXlheUEyU1ctMDZPNTNXSzVtQ2JpXy1WSWZnSnpaMjJfa2FZb3JPdUtpNDlMQ1NRcEJTbzV4UklLS0gzQktQbEdwSkZtcHhpb3htUVhhX3c1dmhOWW83Qmc3M19WQ2dSQnRuVHRGQVZKaUJVR3V0UEVtb1lxcGJjVWE3TT…
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPYjVTalJyWUNkd2gtWng3Nl9kaFB2c0hhVEw3MjZPTVF4c0NlZXEwUFh0N0NKR1FYZ202bkxrZjVMcjBUaTNNTHBDdV9RTzVlalFhY3hzaEx0NGpmM0tYYlp0ekNzUnFiNlZqRmUzX3dzOS1iZ3RKQmIyM2IxSW84OUR4Sk1xY2FFTVE1U2…
Sanity Group Acquisition Boosts Organigram's Quarterly Revenue - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQUHJNVFJaR3o1OGFKbVE1My14NGxjZUtpLUFrSGFLWUY2UGxwNk9iWWU2bDRacmtjbjBiOThFdDNobEhScnQtQjM5RzRFc1h6UGQtTldjdS1Bb0tMdExTS2JZcVYzekZpdDJucDZYZ004NkpqX0s5U2lhSVdQQW5QeVVCcHZ0TlFLOVBBNH…
OGI - Organigram Global Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE1Cem15T0Z1dXJRMnZfdWxDYXFzMXR6bGdQU05VRzZ4ekJidXdrZzl3MnZKclk4SWZuOVRkakVWc0lGa1hH?oc=5" target="_blank">OGI - Organigram Global Inc Stock Price and Quote</a> <font colo…
Organigram Global (TSX:OGI) Stock Rethinks A 2.7x P E After Profit Shock - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMG1VTnI1WVljUjdGRGU0dTBTbXlqUE1EM1E2MFZwNjZpTTVXc1d5M1l2YUtBOC1odndLdk9uSW1hQ2Fua0Q0VGZLc1VVMmsyTXZIeUJUbzR0UWZiajMzeEd1QkZYMVl3aEd3ajl6dnhyR0NBNzVqMlNDRnJjUjR0TENrZ3hWSGQtUll2WW…
Cannabis Stock Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) Makes TSX Top Gainer List on Third Quarter Results - Investorideas.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQU0NLWHVYMVdIU2dtT09TbjNGa3cwRzQ0Qi16bDZNWm1aV25PaW1LSGx2bC11cnkzUnE1aHp2ZmdVQUdFcEhBQk95VGxJYUdOcWlhSlR6VjlqTlprY3NnVkt3RFJBRmZLVFJXUkZ3MTdlekNWR29POWVnN3lIUlVsM0NJVHVqSUtvOW0ybn…
OGI — Frequently Asked Questions
What is the current share price of Organigram Global Inc. (OGI)?
As of 2026-09-19 21:16 PDT, Organigram Global Inc. (OGI) trades at $1.12 on NasdaqGS. Its 52-week range is $0.87 to $2.11.
What is the market capitalisation of OGI?
Organigram Global Inc. (OGI) has a market capitalisation of $157.93M on NasdaqGS.
What is the P/E ratio of OGI?
OGI trades at a trailing price-to-earnings (P/E) ratio of 2.60. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.40.
What is the return on equity (ROE) of OGI?
OGI has a return on equity (ROE) of 17.56%. Its return on capital employed (ROCE) is -3.51%.
Is OGI a good stock to buy?
This page provides a data-driven analysis of Organigram Global Inc. (OGI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.